BDRX · Biodexa Pharmaceuticals Plc · Metrics
Market Cap
$896,022
Shares
2.20M
Volume · Oct 22
96.37K
Avg daily vol (3M)
4.86M
BDRX metrics
47 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.41
Market cap
$896,022
Price action
20 metricsPrice change (1W)
-4.0%
Price change (30D)
-39.9%
Price change (3M)
-75.4%
Price change (6M)
-87.9%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
190.3%
Annualized volatility (3M)
243.6%
Beta
1.2
RSI (14D)
36.4
Price vs SMA 50
-48.9%
Price vs SMA 200
—
Avg volume (3M)
4.86M
Relative volume
0.0
Average dollar volume
$5.14M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
2.20M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.1
reciprocal yield 1,422.5%
FCF yield
-1,034.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2021-06-30
Profitability
9 metricsGross margin
—
Operating margin
-2,103.4%
Trailing 12 months
Net margin
-1,858.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$8.84M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-45.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+33,675.1%
Year over year · more shares
Revenue CAGR (3Y)
+3.6%
Revenue CAGR (5Y)
-27.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-56.0%
Return on assets
-35.1%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$9.27M
Quick ratio
—
Interest coverage
-56.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.28M
Total assets
$16.87M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$9.26M
Capital expenditures (TTM)
$9,397
R&D (TTM)
$7.00M
SG&A (TTM)
—
Stock compensation (TTM)
$165,117
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
8
13F filer change QoQ
0
Institutional ownership
0.8%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-79.1%
Holder tenure
—
Price vs estimated holder cost
—
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
29 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—